| pubmed-article:15072702 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15072702 | lifeskim:mentions | umls-concept:C0085295 | lld:lifeskim |
| pubmed-article:15072702 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:15072702 | lifeskim:mentions | umls-concept:C0018213 | lld:lifeskim |
| pubmed-article:15072702 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:15072702 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:15072702 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15072702 | pubmed:dateCreated | 2004-4-9 | lld:pubmed |
| pubmed-article:15072702 | pubmed:abstractText | The intractability of Graves' disease (GD) and the severity of Hashimoto's disease (HD) vary among patients. We previously reported that peripheral immunoglobulin (Ig) G3-secreting cells were increased in patients with intractable GD (i.e., requiring continuous antithyroid drug therapy). Isotype switching to IgG3 is induced by interleukin (IL)-4 and IL-10. To clarify which of these cytokines is related to the intractability or severity of autoimmune thyroid disease (AITD), we examined the serum concentrations of IL-10 and IL-4 by enzyme immunoassay in 166 patients with AITD and in 53 healthy controls. The serum IL-10 concentration was significantly higher in patients with GD and continuously positive for thyrotropin (TSH) receptor antibody (TRAb) despite more than 5 years of antithyroid drugs treatment than in patients with GD in remission. The serum IL-4 concentration did not differ between these two groups of patients. However, the serum IL-10 concentration was not related to the severity of HD. These results indicate that IL-10, but not IL-4, is related to the intractability of GD, but not to the severity of HD. | lld:pubmed |
| pubmed-article:15072702 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15072702 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15072702 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15072702 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15072702 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15072702 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15072702 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15072702 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15072702 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15072702 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15072702 | pubmed:issn | 1050-7256 | lld:pubmed |
| pubmed-article:15072702 | pubmed:author | pubmed-author:MatsuzukaFumi... | lld:pubmed |
| pubmed-article:15072702 | pubmed:author | pubmed-author:MiyauchiAkira... | lld:pubmed |
| pubmed-article:15072702 | pubmed:author | pubmed-author:IwataniYoshin... | lld:pubmed |
| pubmed-article:15072702 | pubmed:author | pubmed-author:WatanabeMikio... | lld:pubmed |
| pubmed-article:15072702 | pubmed:author | pubmed-author:TakeokaKeikoK | lld:pubmed |
| pubmed-article:15072702 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15072702 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:15072702 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15072702 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15072702 | pubmed:pagination | 201-5 | lld:pubmed |
| pubmed-article:15072702 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:meshHeading | pubmed-meshheading:15072702... | lld:pubmed |
| pubmed-article:15072702 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15072702 | pubmed:articleTitle | Increase of serum interleukin-10 in intractable Graves' disease. | lld:pubmed |
| pubmed-article:15072702 | pubmed:affiliation | Division of Biomedical Informatics, Course of Health Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. | lld:pubmed |
| pubmed-article:15072702 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:3586 | entrezgene:pubmed | pubmed-article:15072702 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:15072702 | lld:entrezgene |
| lhgdn:association:6963 | lhgdn:found_in | pubmed-article:15072702 | lld:lhgdn |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15072702 | lld:pubmed |
